THYTECH
Marta Martínez Bonet has a diverse work experience across multiple research institutions. Marta is currently a co-founder at THYTECH since 2022. Prior to this, they worked as a Postdoctoral Research Scientist at the Instituto de Investigación Sanitaria Gregorio Marañón starting in 2019. Before that, from 2016 to 2019, they held the same position at Brigham and Women's Hospital and Harvard Medical School. Marta'searliest experience in this field was as a Postdoctoral Research Scientist at the Instituto de Investigación Sanitaria Gregorio Marañón from 2014 to 2015.
Marta Martínez Bonet began their education at the Universidad Autónoma de Madrid in 2004, where they obtained a Licenciatura en Bioquímica degree in 2008. Marta continued their studies at the same university and earned a Master's degree in Molecular Bioscience in 2010. Following this, they pursued a Doctor of Philosophy (Ph.D.) in Molecular Biology, which they completed in 2014, also at the Universidad Autónoma de Madrid.
This person is not in any teams
This person is not in any offices
THYTECH
THYTECH is a spin-off of the Gregorio Marañón Health Research Institute (IISGM) that was created with the aim of transferring to the patient our patented technology for the treatment of diseases related to immune disorders. The company arises from the work carried out by the researchers of the Immunoregulation Laboratory, and our main asset is a cellular therapy with thyTreg cells that is pioneering in the world that can establish a new paradigm in the prevention of transplant rejection and in the treatment of autoimmune diseases and clinical worsening of COVID patients.